
    
      The study will be conducted in North America, Europe and the United Kingdom.

      In this single arm study participants will be treated with with durvalumab alone and
      concurrently with platinum-based chemotherapy and etoposide during the study period until
      radiological disease progression, unless there is clinical progression, unacceptable
      toxicity, withdrawal of consent, or another discontinuation criterion is met, as per
      investigator assessment.
    
  